Lesson plan

Aderbasib

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation. Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells. Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research. More specifically, aderbasib is an inhibitor of ADAM10 and ADAM17.

Back to article

Article summary

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation. Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells. Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research. More specifically, aderbasib is an inhibitor of ADAM10 and ADAM17.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.